Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Incyte: Ph3 INCB 39110-309 Itacitinib/Placebo + Corticosteroids in cGVHD - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if the study drug (itacitinib) will work better than the placebo when used together with corticosteroids for moderate or severe chronic GVHD.
What is the Condition Being Studied?
Graft versus- host disease (GVHD)

Who Can Participate in the Study?

Adults who:
- Have GVHD
- Have underwent allo-HCT from any donor HLA type (related or unrelated donor with any degree of HLA matching) using any graft source (bone marrow, peripheral blood stem cells, or cord blood)

Age Group

What is Involved?

If you choose to join this study, you will have:
- A screening visit
- To take the study drug, itacitinib, by mouth
- A physical exam and the doctor will go over any side effects that you may have experienced
- A review of your ability to perform daily activities
- Blood tests
- An ECG/EKG done
- An assessment of your cGVHD symptoms
- To complete Quality of Life questionnaires

Study Details

Full Title
A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft Versus Host Disease (GRAVITAS-309)
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00101558
NCT: NCT03584516
Phase III
Contact the Duke Recruitment Innovation Center